These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Use of dopamine agonists in the treatment of Parkinson's disease]. Gekht AB Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886 [No Abstract] [Full Text] [Related]
3. Second generation of dopamine agonists: pros and cons. Rabey JM J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628 [TBL] [Abstract][Full Text] [Related]
4. Combination of two different dopamine agonists in the management of Parkinson's disease. Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370 [TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
6. GSK's Requip slow the loss of dopamine function in Parkinson's disease. Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117 [No Abstract] [Full Text] [Related]
15. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325 [TBL] [Abstract][Full Text] [Related]
16. Pramipexole, ropinirole, and mania in Parkinson's disease. Singh A; Althoff R; Martineau RJ; Jacobson J Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169 [No Abstract] [Full Text] [Related]
20. New dopamine agonists on the horizon. Heins JR S D J Med; 1997 Jul; 50(7):239-40. PubMed ID: 9240032 [No Abstract] [Full Text] [Related] [Next] [New Search]